[Lead compound optimization strategy(5) – reducing the hERG cardiac toxicity in drug development]

Area of Science:

• Cardiovascular Physiology
• Pharmacology
• Molecular Biology

Background:

• The human ether-a-go-go related gene (hERG) potassium channel is vital for cardiac repolarization.
• Blockade of the hERG channel by certain drugs can lead to serious side effects like long QT interval and arrhythmia.
• Drug-induced hERG channel inhibition poses a significant safety concern, leading to market withdrawals.

Purpose of the Study:

• To outline strategies for optimizing lead compounds to minimize hERG channel inhibitory activity.
• To reduce the risk of cardiac toxicity associated with drug candidates.
• To improve the safety profile of potential therapeutics targeting or interacting with the hERG channel.

Main Methods:

• Reducing the lipophilicity and basicity of amine groups in drug candidates.
• Introducing hydroxyl and acidic functional groups into molecular structures.
• Employing conformational restriction to modulate hERG channel binding.

Main Results:

• These optimization strategies aim to decrease the affinity of compounds for the hERG channel.
• Reduced lipophilicity and basicity are associated with lower hERG channel blockade.
• Incorporating specific functional groups and conformational constraints can enhance selectivity and reduce cardiotoxicity.

Conclusions:

• Lead compound optimization focusing on hERG channel interaction is essential for developing safer drugs.
• Modifying physicochemical properties and molecular conformation can effectively mitigate hERG-related cardiac risks.
• These strategies provide a framework for improving drug safety and reducing the incidence of arrhythmia.